Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-992 in Subjects With Advanced Solid Tumors

NCT06480240 is registered in ClinicalTrials.gov with OBI Pharma, Inc as lead sponsor.

NCT NCT06480240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06480240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-992 in Subjects With Advanced Solid Tumors
Lead sponsor
OBI Pharma, Inc
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 12, 2024
Completion date
June 30, 2027
Enrollment
117 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor